Tesamorelin vs MOTS-c
Compare the research profiles of Tesamorelin and MOTS-c. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesTesamorelin
Tesamorelin (Egrifta)
growth-hormone
Phase 4 (Post-Market)
approved
MOTS-c
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c)
mitochondrial
Preclinical
not-approved
Detailed Comparison
| Aspect | Tesamorelin | MOTS-c |
|---|---|---|
| Overview | An FDA-approved GHRH analog originally for HIV-associated lipodystrophy. Increasingly used off-label for abdominal fat reduction and muscle growth. One of the few FDA-approved GH-related peptides.... | A mitochondrial-derived peptide described as an "exercise mimetic" that may improve glucose metabolism and physical stamina even without training. Naturally produced during exercise.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone naturally. Unlike synthetic HGH, it works through the body's own regulatory mecha... | Encoded in mitochondrial DNA, MOTS-c activates AMPK pathway and improves glucose uptake in skeletal muscle. May mimic some metabolic benefits of exerc... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.